高血壓 高尿酸 慢性腎病 胰島素 https://2019medicinenote.blogspot.com/2019/12/blog-post_57.html . 糖尿病相關筆記~目錄 https://2019medicinenote.blogspot.com/2020/01/blog-post_4.html

2019年12月28日 星期六

DPP4i 二肽基酶-4 抑制劑

腎衰竭/慢性腎病CKD
  • 可以使用
  • Linagliptin (Trajenta)在腎衰竭病患不用減量
  • 其他DPP4i 藥物需減低劑量
DPP4i 包含幾種藥物, 腎衰竭可以使用, 但需降低劑量 (linagliptin 不用降低劑量)
Vildagliptin= Galvus
Sitagliptin= Januvia
Saxagliptin= Onglyza
Linagliptin= Trajenta 腎衰竭不用降低劑量
Alogliptin= Vipidia
Stiagliptin + Metformin= Janumet
Vidagliptin Metformin=Eucreas
Alogliptin Metformin= Vipdomet
Linagliptin Metformin= Jentadueto
Saxagliptin Metformin= Kombolyze

GLIPTINS (DIPEPTIDYL PEPTIDASE 4 INHIBITORS)
Dipeptidyl peptidase 4 (DPP-4) inhibitors (gliptins) constitute a new class of antidiabetic drugs with a very favorable profile: safety, efficacy, and low risk of hypoglycemia and weight neutrality[22].

Gliptin 藥物能抑制 DPP4, DPP4是一種酵素, 可以將很多活性胜肽降解及去活性, 主要是指腸泌素 incretin , 腸泌素包含 GLP-1 及 GDIP, 可刺激胰臟的b細胞分泌胰島素, 腸泌素也會抑制胰臟的昇糖素 glucagon 產生, 腸泌素對於葡萄糖平衡相當重要, 空腹的時候腸泌素分泌下降, 餐後快速分泌, 腸泌素作用結果也會降低昇糖素分泌, 進一步減少肝臟產生的葡萄糖

Gliptins are inhibitors of the enzyme DPP-4. This enzyme degrades and inactivates many active peptides. Among them are incretin hormones. These hormones, namely glucagon like peptide 1 (GLP-1) and glucose dependent insulinotropic polypeptide stimulates glucose dependent insulin secretion by b cells in pancreatic islets. At the same time they suppress glucagon production by a cells in the same islets. Their role in glucose homeostasis seems to be important. These hormones are secreted in low levels when we are fasting but their secretion is rapidly increased after meal consumption. Their action results also in reduced glucagon secretion, which in turns reduces hepatic glucose production.

Vildagliptin, Sitagliptin, Saxagliptin, Linagliptin and Alogliptin belong to this class and are already available in the market. Their place in algorithms for patients with diabetes and CKD is important. We can use them all in CKD but with dose adjustment for the majority of the members of this class. (Only linagliptin does not need dose adjustment in any stage of CKD)[23].
In Table ​Table22 we summarize the dose adjustments for all gliptins in diabetic subjects with CKD.


效果:中等
低血糖:低
體重:無影響
副作用:少見
心血管實證:中立

SitagliptinSaxagliptinVildagliptinLinagliptinAlogliptin










沒有留言:

張貼留言

幼兒專責醫師-新生兒黃疸

2026-03-26 09:16AM 衛生福利部-幼兒專責醫師實務參考手冊電子版 圖片: 台灣新生兒科醫學會-新生兒延長性黃疸處置建議 2018.05.04 測定『直接及總膽紅素並求其比值』:當新生兒的黃疸超過出生後 14 天時,建議於 30 天大之前,至少檢測一次血中直接及總膽...